FGFR2c mesenchymal isoform expression is associated with poor prognosis and further refines risk stratification within endometrial cancer molecular subtypes.

CONCLUSIONS: FGFR2c expression appears an independent prognostic biomarker in endometroid EC patients and further discerns the outcomes within grade 3 tumours, ESMO high-risk groups, as well as within the MMRd and p53wt subtypes. FGFR2c inclusion into future molecular subtyping can further refine risk stratification of endometrioid EC. PMID: 32414751 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32414751?dopt=Abstract

Source: Clinical Cancer Research - May 14, 2020 Category: Cancer & Oncology Authors: Sengal AT, Patch AM, Snell CE, Smith DS, Leung S, Talhouk A, Williams ED, McAlpine JN, Pollock PM Tags: Clin Cancer Res Source Type: research